Profile data is unavailable for this security.
About the company
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-20.62m
- Incorporated2011
- Employees6.00
- LocationNeximmune Inc9119 Gaither RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (301) 825-9810
- Fax+1 (302) 636-5454
- Websitehttps://www.neximmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
eFFECTOR Therapeutics Inc | 0.00 | -34.63m | 192.69k | 14.00 | -- | 0.1933 | -- | -- | -13.31 | -13.31 | 0.00 | 0.2119 | 0.00 | -- | -- | 0.00 | -141.18 | -- | -- | -- | -- | -- | -- | -- | -- | -17.12 | 0.9581 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
CNBX Pharmaceuticals Inc | 230.08k | -1.21m | 211.56k | 2.00 | -- | -- | -- | 0.9195 | -0.0458 | -0.0458 | 0.0081 | -0.0789 | 0.6201 | -- | -- | 115,040.00 | -325.63 | -73.32 | -- | -99.80 | 14.96 | -- | -525.10 | -3,970.88 | -- | -1.34 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
Drazcanna Inc | 2.05m | -5.71m | 218.89k | -- | -- | -- | -- | 0.1069 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
Propanc Biopharma Inc | 0.00 | -2.46m | 223.10k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
Meso Numismatics Inc | 2.87m | -10.15m | 330.28k | 1.00 | -- | -- | -- | 0.115 | -0.8144 | -0.8144 | 0.2303 | -2.07 | 0.5424 | -- | 76.15 | -- | -191.67 | -192.08 | -- | -- | 68.95 | 60.24 | -353.35 | -821.49 | 0.0257 | -0.0755 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
Neximmune Inc | 0.00 | -20.62m | 348.67k | 6.00 | -- | 0.5007 | -- | -- | -18.59 | -18.59 | 0.00 | 0.66 | 0.00 | -- | -- | 0.00 | -140.56 | -115.07 | -224.94 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
Cannabis Global, Inc. | 2.62m | -3.16m | 431.88k | 3.00 | -- | 0.0172 | -- | 0.1649 | -0.0324 | -0.0324 | 0.008 | 0.0058 | 0.1929 | 14.13 | 5.92 | -- | -27.77 | -164.57 | -140.92 | -- | -2.45 | -- | -143.95 | -831.07 | 0.1799 | -1.75 | 0.3238 | -- | 5,829.78 | -- | -58.94 | -- | -- | -- |
NovAccess Global Inc | 0.00 | -1.74m | 441.57k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
Endonovo Therapeutics Inc | 255.72k | -4.40m | 444.45k | 0.00 | -- | -- | -- | 1.74 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Sabby Management LLCas of 30 Jun 2024 | 49.90k | 3.58% |
Slate Path Capital LPas of 30 Jun 2024 | 37.00k | 2.65% |
EPIQ Capital Group LLCas of 30 Jun 2024 | 15.62k | 1.12% |
PNC Bank, NA (Investment Management)as of 30 Jun 2024 | 12.64k | 0.91% |
Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 10.80k | 0.78% |
JPMorgan Securities LLC (Investment Management)as of 30 Jun 2024 | 4.00k | 0.29% |
Tower Research Capital LLCas of 30 Jun 2024 | 2.12k | 0.15% |
UBS Securities LLCas of 30 Jun 2024 | 638.00 | 0.05% |
RBC Dominion Securities, Inc.as of 30 Jun 2024 | 102.00 | 0.01% |
BNP Paribas Financial Marketsas of 30 Jun 2024 | 41.00 | 0.00% |